Biotech VC Funds

iSeed Ventures, founded in 2014, is a venture capital firm based in San Francisco, California, that focuses on seed-stage investments in sectors such as digital health, the Internet of Things (IoT), and consumer technology. The firm aims to support innovative startups with high growth potential and has a diverse portfolio of companies across various industries. Some of the notable investments by iSeed Ventures include 9am.health, a virtual diabetes clinic that secured $3.7 million in seed funding to provide better diabetes care in the U.S., and CoderSchool, an online coding education platform based in Vietnam, which raised $2.6 million in pre-Series A funding to expand its reach. Other significant investments include Jeff, a fintech company focused on lending, and AvalonMeta Ventures, which combines education and gaming. iSeed Ventures is known for its commitment to supporting early-stage startups through strategic investments and active mentorship. The firm typically makes investments with an average round size of $2 million and has been involved in various rounds annually, showcasing its active role in the venture capital ecosystem.

iSelect Fund is a St. Louis-based venture capital firm focusing on early-stage investments in sectors that have a profound global impact, such as agriculture, food, and healthcare. They invest in companies addressing critical challenges like sustainable food production, improved healthcare delivery, and innovations that enhance human health through better nutrition. iSelect’s portfolio includes over 60 companies, such as Harpe Bioherbicide and Kula Bio, which are tackling sustainability in agriculture through natural and biotechnological solutions. The firm operates with an evergreen fund structure, offering ongoing investment opportunities with low minimums, making venture capital more accessible to accredited investors. Their investment strategy revolves around a balanced, diversified portfolio approach, which allows them to spread risk while supporting transformative companies. iSelect focuses on startups that leverage data, technology, and science to drive innovation, particularly in the areas of food systems, agtech, and health tech. Their emphasis on impact investing means they are highly selective, looking for businesses with the potential for significant financial returns as well as positive societal outcomes. They typically avoid sectors like cannabis and direct-to-consumer models, and focus on companies that can create long-term, scalable change.

Isomer Capital is a London-based venture capital firm that operates as a "fund of funds," primarily investing in early-stage European tech VCs. Founded by Joe Schorge, Isomer has built a reputation for backing some of Europe's leading venture firms like Seedcamp, Hoxton Ventures, and Entrepreneur First, giving it exposure to high-potential startups across various sectors. With over 70 VC firms and 29 unicorns in its portfolio, Isomer Capital focuses on identifying promising early-stage ventures across Europe. Notable investments include companies like UiPath, Deliveroo, and Wefox. Their strategy includes direct co-investments in top-performing startups when they are ready to scale, secondary investments, and a strong commitment to providing liquidity solutions to founders and early investors. Their latest fund, Isomer Capital III, targets €250 million, continuing their focus on European growth-stage startups. They plan to deploy this fund over the next few years, with key supporters such as British Business Investments and the European Commission.

Israel HealthCare Ventures (IHCV) is a leading Israeli life sciences venture capital fund founded in 2000 and based in Tel Aviv. The firm has raised two funds, IHCV I and IHCV II, cumulatively investing approximately $135 million across 27 companies in Israel-based startups. Founder and Managing Partner Hadar Ron leads the firm with a hands-on investment approach, preferring to hold board seats in portfolio companies and providing professional advice, ongoing management support, and access to a global network of medical and financial contacts. IHCV invests from seed to later stages across medical devices, biotechnology, pharmaceuticals, life sciences, nanotechnology, and medical-related IT. Approximately 75% of the portfolio consists of medical device companies, with the remaining 25% in pharmaceuticals and biotechnology. Investment checks are typically in the $3 million to $10 million range, and the firm leads rounds. The portfolio spans medical fields including cardiology, orthopedics, oncology, general surgery, gastroenterology, esthetics, and central nervous system disorders, covering therapeutic and diagnostic technologies as well as rehabilitation, drug delivery, and consumer healthcare. Co-investors include Teva Pharmaceuticals. The portfolio has achieved 3 IPOs and 3 acquisitions. The most significant exit is Mazor Robotics, a surgical robotics company acquired by Medtronic for $1.7 billion in September 2018. Gamida Cell, a cell therapy company, completed its NASDAQ IPO in October 2018, raising $139 million in total. Xylo Technologies also achieved an IPO exit. Other notable companies in the portfolio include CorAssist, OrSense, and Optonol. IHCV's two-decade track record in Israeli life sciences reflects the firm's consistent focus on technology that addresses large patient populations with unmet clinical needs. The firm's extensive global medical network enables portfolio companies to access regulatory expertise, clinical partnerships, and commercial relationships across the United States, Europe, and Asia.

Israel Secondary Fund (ISF) is a pioneering secondary investment firm established in 2008, focusing on providing liquidity solutions within Israel's high-tech ecosystem. Headquartered in Herzliya, ISF has built a robust presence in the secondary market by facilitating over 80 transactions, offering stakeholders opportunities to sell their interests in tech companies and venture funds. The firm manages over $500 million, catering to needs ranging from direct secondary purchases of shares from founders and employees to acquiring LP positions in VC and private equity funds. ISF’s strategy centers on its "Triple Win Approach," ensuring mutual benefits for sellers, ISF, and the companies involved. They conduct transactions typically starting from $1 million, becoming long-term partners to their portfolio companies, which include notable names like MyHeritage, Aidoc, and Verbit. This involvement often extends to participating in future funding rounds and structured deals that provide liquidity while preserving the growth potential of the assets. The firm is led by experienced partners, including co-founders Dror Glass and Shmuel Shilo, who leverage decades of expertise in investment and finance. ISF recently raised $312 million for its third fund, highlighting its critical role in enabling liquidity in a market where startups might face long pathways to exits, especially amid IPO delays. By offering these tailored liquidity solutions, ISF continues to support the sustained growth of Israel’s tech sector.

IST Cube is a venture capital fund based in Austria, focusing on science-based startups and academic spin-offs that are pioneering innovative solutions in deep tech and other high-impact sectors. Founded in partnership with the Institute of Science and Technology Austria (IST Austria), IST Cube is designed to help early-stage companies commercialize breakthrough technologies derived from academic research. The fund primarily targets investments in deep tech sectors such as IT, healthcare, energy, and advanced materials. With a typical investment range between €1 million and €2 million, IST Cube supports startups from pre-seed to later stages, with a strong focus on long-term development and growth. The firm is committed to backing companies that combine cutting-edge science with scalable business models. IST Cube provides its portfolio companies with more than just capital. The fund also offers strategic guidance, mentorship, and access to a broad network of industry experts and collaborators. Startups benefit from IST Cube's deep understanding of intellectual property, business development, and technology transfer, which helps founders navigate the complexities of scaling science-driven innovations. Some of IST Cube's notable investments include Prewave, an AI-driven supply chain monitoring platform, and contextflow, a company specializing in AI-powered medical imaging solutions. By bridging the gap between academic innovation and market application, IST Cube is fostering the next generation of groundbreaking technologies.

IT-Farm is a venture capital firm that focuses on early-stage technology startups with transformative potential. Founded in 1999, IT-Farm is based in Tokyo, Japan, and has expanded its reach to include investments in North America and Asia. The firm has a strong track record of supporting innovative companies in sectors such as IT, AI, IoT, and cleantech. Some notable startups in IT-Farm's portfolio include Plus One Robotics, which offers industrial robotics solutions for material handling in e-commerce, and TerraClear, an ag-tech company specializing in automated rock-picking solutions for agriculture. These investments highlight IT-Farm's commitment to backing companies that address significant industry challenges through advanced technology​. IT-Farm's investment strategy emphasizes hands-on support and strategic guidance, helping startups navigate early-stage development and scale their operations. The firm provides critical resources beyond capital, such as mentorship and connections to a global network of industry experts and potential partners. The team at IT-Farm includes experienced investors and industry veterans who bring a wealth of knowledge and expertise to their portfolio companies. This collaborative approach has been instrumental in fostering innovation and driving growth across various technology sectors.

ITIC (Industrial Technology Investment Corporation) is a venture capital arm of Taiwan's Industrial Technology Research Institute (ITRI), founded in 1979. Over the years, ITIC has invested more than $400 million across a wide range of sectors, including semiconductors, biotech, precision machinery, and automotive technologies. The firm focuses on both early and growth-stage investments, leveraging the vast technical expertise and resources of ITRI, which includes over 6,000 researchers and 25,000 patents. What sets ITIC apart is its deep involvement in R&D and the global ecosystem of partnerships it has built over four decades, connecting startups with manufacturers, market intelligence, and corporate partners. Some of its notable portfolio companies include UMC and AUO. ITIC also manages various funds, such as the Golden Asia Fund and the Digital Economy Fund, targeting emerging tech trends like AI, IoT, and advanced materials. ITIC’s CVC (Corporate Venture Capital) program helps established companies invest in startups that align with their strategic goals, reducing risks through expert guidance and post-investment support.

IU Ventures is a 501(c)(3) affiliate of Indiana University focused on investing in and supporting early-stage, IU-affiliated startup companies, generating social and economic impact for the university, Indiana, and beyond. Founded in 1997 and based in Bloomington, Indiana, the organization is led by Tony Armstrong, President and CEO since 2008, and Jason Whitney, Chief Venture Officer and Executive Director, with a team of 28 members including 12 partners. IU Ventures manages three investment programs: the IU Angel Network, the $11 million IU Philanthropic Venture Fund established in 2018 as an evergreen fund, and the Innovate Indiana Fund established in 2010 and now fully invested. The firm leads rounds across pre-seed and seed stages, with checks from $100,000 to $1 million. The portfolio includes 68 companies across life sciences, health technology, enterprise software, fintech, and consumer sectors. IU Ventures focuses on Indiana University's traditional strengths in life and health sciences alongside emerging areas including engineering, cybersecurity, quantum computing, and big data analytics. The portfolio has achieved 1 IPO and 14 acquisitions. MBX Biosciences listed on NASDAQ in September 2024 at a $510 million market cap, the most notable exit. Other acquisitions include Sharpen, PrecisionHawk, Doxly, Encamp, Mentor Collective, Canopy, Probari, Diagnotes, and Qumulex. IU PhV portfolio companies include Confluence Pharmaceuticals, Nerx BioSciences, Scioto Biosciences, NuCurrent, Amplified Sciences, Boardable, MetaCX, and Monument Biosciences. The firm led a $1.9 million seed round of Adipo Therapeutics alongside VisionTech Partners and Elevate Ventures. The most recent investment was in Membershine in December 2025. IU Ventures has received the Mira Award for Investor of the Year for its commitment to investing in diverse founding teams. The organization's university affiliation gives it a direct pipeline to faculty-led spinouts, graduate student ventures, and commercialized research, creating a deal flow channel unavailable to conventional institutional funds.

J.F. Shea Ventures (Shea Ventures) is the corporate venture capital division of J.F. Shea Co., Inc., a family-owned company with origins tracing to 1881, when John Francis Shea founded the business in Portland, Oregon. The venture arm was established in 1968, making it one of the oldest corporate venture capital programs in the United States. Based in Walnut, California, Shea Ventures stewards the Shea family's wealth generated through its parent company's construction, homebuilding through Shea Homes, commercial real estate through Shea Properties, and heavy construction businesses. Managing Director John C. Morrissey leads a team of five. The venture division has invested in 161 companies across 9 funds, with 52 exits, and remains a SEC-registered investment adviser. Shea Ventures helped make the technology revolution a reality through early investments in companies that grew into industry leaders, including Compaq Computer Corporation, Altera Corp, Brocade Corp, and Exodus Corp. Today the firm invests at seed, early, and later stages in software including web marketplaces and SaaS platforms, semiconductors, biotechnology, and medical devices, with checks typically in the $1 million to $10 million range. Investments span Silicon Valley through to the eastern United States. The most recent investment was in Sorcero, an AI-powered life sciences content intelligence company, at Series B in October 2025. The most recent exit was NEXT Trucking, a digital freight marketplace, in February 2024. Shea Ventures operates with the patient capital orientation typical of a family office, maintaining positions across long investment cycles without the fund-life pressures that constrain institutional vehicles. This structure allows the firm to support portfolio companies through multiple rounds and market cycles, and has enabled a consistent track record of backing technology and life sciences companies from early formation through to significant exits over more than five decades.

January Ventures is a forward-thinking venture capital firm committed to investing in early-stage B2B startups that are digitally transforming traditional industries. Co-founded by Maren Bannon and Jennifer Neundorfer, the firm is dedicated to supporting ambitious founders who are often overlooked by traditional VC networks. The fund's notable investments include companies like Clarity Pediatrics, a health tech startup, and Treefera, a data platform for environmental sustainability. January Ventures is known for its strong community of founders, particularly from underrepresented backgrounds, providing not only financial support but also strategic guidance and operational advice. Geographically, January Ventures focuses primarily on the U.S. but has a presence in London, reflecting their global outlook. They emphasize a hands-on approach, frequently leading rounds and staying actively involved with their portfolio companies through various stages of growth. January Ventures' team brings a wealth of experience from diverse backgrounds. Maren Bannon, based in London, has a rich history in marketing and product roles at companies like Genentech and Roche. Jennifer Neundorfer, based in Boston, has a background in media and advertising, having worked at YouTube and 21st Century Fox. Together, they leverage their deep industry knowledge and extensive networks to help startups succeed. The firm prides itself on compassionate collaboration, providing founders with honest feedback and essential resources, from PR strategy to hiring and fundraising. This approach has earned January Ventures a reputation as a highly supportive and impactful investor in the startup ecosystem.

Jaza Rift Ventures is an impact investment firm founded in 2022 and based in Nairobi, Kenya, with additional offices in Accra, Ghana, and Luxembourg. Launched in partnership with Villgro Africa, the firm is exclusively focused on healthcare in Africa. The maiden Jaza Rift Pioneers Fund is a $5 million impact VC fund deploying checks of $100K to $500K at pre-seed, seed, and seed-extension stages into healthtech, medtech, and biotech founders across the continent. The firm also targets a larger $50 million fund for early-stage investments in digital health, medtech, and biotech. Jaza Rift leads rounds within its portfolio. The firm is a recognized Beyond The Billion partner. Managing Partner Sewu-Steve Tawia brings more than 20 years of experience in development finance, consulting, angel investing, and venture capital across Europe and Africa. Tawia holds CAIA and CIFE certifications and is an alumnus of London Business School, Audencia Business School, and Stanford GSB. The partnership with Villgro Africa provides access to a pipeline of more than 1,600 startups, with 20 identified as potential fund returners. Portfolio companies include Taneel (life and health insurance), Neopenda (medical devices for emerging markets), Plural Health (enterprise healthcare systems), and YeneHealth (Ethiopian femtech, where Jaza Rift led the pre-seed round in July 2023). Jaza Rift's thesis is straightforward: affordable, accessible, and high-quality healthcare in Africa represents both an urgent social need and a significant investment opportunity. The firm provides the '4Cs' framework alongside a network of advisors spanning biotech, medtech, and digital health to help portfolio founders navigate the unique challenges of building healthcare businesses across African markets.

Jazz Venture Partners, founded in 2015 and based in San Francisco, is a leading venture capital firm focusing on technologies that enhance human performance. They have a diverse portfolio that includes notable companies like Sounding Board, KLOWEN Braces, Robust.AI, AppliedVR, Pymetrics, Embodied, and Mahana Therapeutics. Their investment strategy is centered on early-stage startups, particularly at the pre-seed, seed, and Series A stages, and they focus heavily on sectors like EdTech, HR Tech, software, health and wellness, robotics, and AI/ML. Geographically, Jazz primarily invests in U.S.-based companies but maintains a global perspective. Their approach includes backing innovative companies that leverage cutting-edge neuroscience and digital technologies to push the boundaries of human potential. They have successfully exited several investments, including Akili Interactive, which went public, and Pymetrics, acquired in 2022. Jazz Venture Partners typically writes checks in the range of $500K to $3M and is open to connecting with startups through their extensive network. They build their investment funnel through a combination of proactive scouting and leveraging their robust network in the tech and science communities​.

Jeito Capital is a global private equity fund specializing in life sciences, with a strong focus on biopharma companies. Founded in Paris, Jeito supports breakthrough innovations that address critical unmet medical needs. The fund's mission is centered on improving patient outcomes through targeted investments in early-stage and growth-stage biopharma companies, particularly those working on therapies for life-threatening diseases. Jeito operates with a unique long-term investment strategy, providing continuous financial support from clinical development through to market access. This allows its portfolio companies to achieve significant milestones while accelerating drug development. The fund has a diverse portfolio of companies, including SparingVision, which is developing gene therapy treatments for inherited retinal diseases, and CatalYm, a biopharma firm working on novel cancer immunotherapies. With over €534 million under management, Jeito's integrated team of experts spans the entire drug development value chain, offering portfolio companies not only capital but also strategic guidance in areas like regulatory affairs, clinical trials, and commercialization. Jeito’s investment approach is also distinguished by its emphasis on global impact, working across Europe and the United States to bring life-saving treatments to market. Jeito has rapidly become a significant player in the life sciences sector, driven by its patient-centered philosophy and focus on fostering the growth of biotech companies that are on the cutting edge of medical innovation.

Jerusalem Venture Partners (JVP), founded in 1993 by Dr. Erel Margalit, is a leading international venture capital firm headquartered in Jerusalem, with additional offices in New York, Tel Aviv, and Be’er Sheva. The firm focuses on early to growth-stage investments across various sectors including cybersecurity, big data, fintech, foodtech, and digital health. Notable investments by JVP include CyberArk, QlikTech, and Earnix. CyberArk is renowned for its cybersecurity solutions and went public on NASDAQ. QlikTech, a cloud-based business intelligence platform, also had a successful NASDAQ IPO. Earnix, which provides AI-based analytics solutions for insurers and banks, achieved unicorn status with its significant valuation. JVP has raised over $1.4 billion across multiple funds and has a strong track record of successful exits. The firm supports its portfolio companies through the Margalit Startup City model, which offers office space, management support, and strategic guidance in dynamic creative campuses located in Jerusalem and New York. These centers foster innovation and collaboration among startups, entrepreneurs, and strategic partners​.

iangmen Ventures, established in 2015, is an early-stage venture capital firm based in Beijing, China. The firm focuses on investing in tech-driven startups, particularly those in sectors such as artificial intelligence, healthcare, IoT, and enterprise computing. Their strategy revolves around leveraging technological innovation to unlock business value, primarily targeting early-stage companies that show significant growth potential. Jiangmen has invested in over 50 startups across various industries, including notable companies like Hesai Technology and Heisenberg Robotics. The firm is known for its commitment to backing companies involved in frontier technology such as quantum computing, AI-powered platforms, and advanced manufacturing. One of its more recent investments includes MyTwins.ai, a Hangzhou-based AI platform. Co-founded by Vanessa Gao and Qiang Shen, Jiangmen Ventures takes a hands-on approach with portfolio companies, offering not only financial backing but also strategic mentorship to help startups scale effectively. The firm places a strong emphasis on innovative solutions that can disrupt traditional industries and foster industrial upgrades, particularly in China’s rapidly growing tech landscape.

Johnson & Johnson Innovation is a global network dedicated to empowering healthcare innovators. Founded in 2012, JLABS supports early-stage companies in the pharmaceutical, medical device, consumer, and health tech sectors. Their mission is to foster the development of life-saving and life-enhancing health solutions. JLABS operates across multiple locations, including San Diego, San Francisco, Cambridge, Shanghai, and New York. They offer a robust infrastructure and resources to startups, facilitating collaboration and growth. The initiative has made over 400 investments, including notable companies such as Capstan Therapeutics and Synthis Therapeutics, focusing on biotechnology and medical devices. Their investment strategy emphasizes strategic partnerships and co-investments, working alongside various industry leaders and funding bodies to maximize impact. Recent investments include support for companies like Immunyx, Grapheal, and Neurogene, showcasing their commitment to advancing innovative healthcare solutions.

JME Venture Capital, established in 2009, is a prominent venture capital firm based in Madrid, Spain. It focuses on early-stage technology startups, investing primarily in Spanish companies with notable expansions across Europe and occasional investments in the US. The firm has raised three funds with over €120 million in assets under management (AUM), investing between €100k and €3m per deal. JME's investment portfolio includes successful companies like Flywire, Jobandtalent, and Voi. Their investment strategy targets sectors such as fintech, healthtech, and blockchain technology. Notably, JME has invested in over 70 startups, leading to significant exits including companies like Volava and Waynabox. The team at JME Venture Capital is led by Samuel Gil and Javier Alarcó, who emphasize a fast and transparent investment process. They support founders with global-scale resources while allowing them to maintain control over their vision and operations​.

Join Capital is a Berlin-based venture capital firm specializing in early-stage investments in deep tech and industrial tech startups. They focus on sectors such as manufacturing, construction, logistics, and enterprise software. Their investment strategy emphasizes helping European deep tech startups achieve significant growth and traction. Join Capital provides not only financial backing but also extensive support through their 360-degree support series, which includes talent selection, sales development, and strategic alignment. Some of their notable investments include Frenetic, a company pioneering custom magnetics technology, and Generative Engineering, which aims to revolutionize physical engineering processes. These investments reflect Join Capital's commitment to backing innovative solutions that address complex industrial challenges. Join Capital is led by a team of experienced professionals who bring a wealth of knowledge in both technical and business fields. This combination enables them to effectively mentor and support startups from inception to market leadership. The firm’s approach is highly collaborative, working closely with founders to transform technical expertise into successful business ventures. For startups looking to engage with Join Capital, it's crucial to present innovative deep tech solutions with clear potential for industrial application and scalability. The firm values strong technical foundations paired with a vision for significant market impact.

Joyance Partners, established in 2017, is a venture capital firm based in San Francisco, California. The firm focuses on investing in early-stage companies that use science and technology to cultivate joy, aiming to improve the way we live. Joyance Partners has made significant investments in health and consumer sectors, targeting companies from pre-seed to Series A stages across North America, Europe, and Asia. Their notable investments include ClosedLoop, which uses AI to identify at-risk patients and recommend interventions, and Copper Cow Coffee, which delivers a premium Vietnamese coffee experience. Another standout is Cubby, which creates smart beds designed to improve anxiety, sleep, and safety for individuals with cognitive disabilities such as Autism and Epilepsy. Joyance Partners also backs innovative companies in beauty and sustainability, like Conserving Beauty, which focuses on solutions-based skincare, and Electric Era, which works on sustainable energy solutions. The firm has made over 500 investments and boasts more than 200 exits, reflecting a strong track record in nurturing and scaling startups. They support companies that promise to enhance personal health, happiness, and well-being through technological advancements. The leadership team, including Managing Partner Michael Edelhart and Founding Partner William Lohse, leverages their extensive experience to guide their portfolio companies towards growth and success. Joyance Partners continues to be an influential player in the venture capital landscape, dedicated to investing in transformative technologies that bring joy to people's lives​.

Joyful Ventures is a venture capital fund dedicated to transforming the global food system through sustainable proteins. With a focus on early-stage investments, Joyful targets alternative protein startups using plant-based, fermentation, and cultivated technologies. Founded by Milo Runkle, Jennifer Stojkovic, and Blaine Vess, the fund aims to disrupt traditional food production and address urgent climate issues. Their $23M fund supports companies developing innovative, humane, and scalable food solutions that outcompete animal-based products on cost, taste, and convenience. Joyful Ventures prioritizes founders facing early-stage challenges, especially underrepresented groups, and actively engages with its portfolio, providing mentorship and leveraging a vast network to accelerate growth. They believe in long-term collaboration and are action-oriented, with a clear commitment to nurturing relationships and driving results​. Their notable investments include startups in cultivated and plant-based meat, like Bosque Foods and Ohayo​. The fund's leadership brings decades of experience in food activism and tech innovation, positioning Joyful Ventures as a driving force in building a more sustainable and inclusive food industry​.

JSR Corporation, headquartered in Tokyo, Japan, is a multinational company specializing in digital solutions, life sciences, and elastomers. Founded in 1957, JSR initially focused on synthetic rubbers but has since expanded its operations to become a leading global supplier in various technology-driven markets. One of JSR's major areas of expertise is semiconductor materials, where they produce lithography materials, CMP materials, and packaging solutions essential for semiconductor chip production. The company has also made significant strides in the life sciences sector, providing services and materials for drug discovery, diagnostics, and bioprocessing. They acquired companies like KBI Biopharma and Selexis to strengthen their capabilities in this field. JSR is also heavily involved in advanced semiconductor technologies. They acquired Inpria Corporation, a leader in metal oxide photoresist technology for extreme ultraviolet (EUV) lithography, to bolster their semiconductor materials portfolio. This acquisition aligns with JSR's strategy to enhance their presence in advanced semiconductor manufacturing processes. Moreover, JSR collaborates with Cambridge Quantum Computing (CQC) on quantum computing projects to develop state-of-the-art quantum algorithms. This partnership highlights JSR's commitment to staying at the forefront of technological innovation. Overall, JSR Corporation leverages its extensive R&D capabilities and strategic acquisitions to maintain its leadership in the semiconductor and life sciences industries, continuously driving innovation and value creation for its global customers.

JumpStart Ventures is a Cleveland, Ohio-based venture capital firm and the investing arm of JumpStart Inc., a nonprofit economic development organization. Founded in 2011, the firm manages more than $200 million across four distinct funds: the Evergreen Fund, Focus Fund, Healthcare Collaboration Fund, and NEXT Fund — providing a continuum of capital from pre-seed through seed and Series A stages. JumpStart Ventures is led by Managing Partner Hardik Desai and has invested in more than 180 high-potential early-stage startups throughout Ohio and the Midwest, delivering top-quartile returns in early-stage B2B SaaS and healthcare. The NEXT Fund III held its first close at $24.55 million toward a $50 million target in March 2025, supported by SSBCI Ohio and 21-plus LPs, with plans to back approximately 15 new startups. JumpStart leads rounds across its portfolio. The firm's most notable exit is CoverMyMeds, an early-stage investment that was acquired by McKesson for more than $1.4 billion — nine years after the initial investment. The firm has recorded more than 30 total exits through acquisitions, including Able Software, Wireless Environment, CardioInsight, Vizzle, and OnShift. Current portfolio companies include Abre (education technology), Centerline Biomedical (medical devices), OnStation (construction tech), Cleveland Diagnostics (cancer diagnostics), Orthobrain (orthodontics AI), and Axuall (healthcare workforce credentialing). Focus sectors span enterprise software, data analytics, biomedical technology, insurtech, fintech, and life sciences. JumpStart Ventures targets companies with greater than $1 billion addressable markets, unique or disruptive solutions, and capital-efficient models. The nonprofit parentage of JumpStart Inc. gives the firm a distinctive economic development mission — supporting Ohio and Midwest entrepreneurs who are often overlooked by coastal investors, while generating the financial returns needed to sustain the broader organization's work.

K Fund is a venture capital firm based in Madrid, Spain, focused on backing tech-driven startups across Southern Europe and Latin America. Founded in 2016, K Fund invests from pre-seed to Series B stages, with check sizes ranging from €100K to €10 million. Their mission is to support visionary, unconventional entrepreneurs who are building scalable, technology-based solutions. The firm’s portfolio includes successful ventures such as Factorial, Exoticca, Voicemod, and Urbanitae, reflecting a diverse range of sectors including SaaS, fintech, travel, and AI. K Fund recently expanded its global footprint by establishing a local presence in São Paulo, Brazil, through their Leadwind fund. This initiative, launched with strategic partners like Telefónica and BBVA, targets deep tech scaleups and aims to bridge the startup ecosystems of Southern Europe and Latin America. Leadwind focuses on sectors like AI, IoT, and blockchain, with the goal of fostering collaboration between these two regions. The fund plans to raise €250 million, making investments starting at €5 million, to help scale these innovative businesses globally. K Fund also emphasizes ESG principles, recently publishing their first impact report, and has committed to promoting sustainability and diversity within their portfolio. Led by a team of seasoned professionals including Miguel Arias and Gustavo S. Carvalhal Ribas, K Fund continues to grow its influence, supporting startups that aim to disrupt traditional markets with cutting-edge technology and scalable business models.

K5 Global is a venture capital firm and incubation studio founded in 2018 by Michael Kives and Bryan Baum. Based in San Francisco, the firm supports founders throughout the entire business lifecycle, from seed stages to IPOs. K5 Global has deployed over $1.1 billion in capital and has made 174 direct investments, resulting in 11 exits. Their portfolio includes high-profile companies such as SpaceX, Uber, Coinbase, Lyft, and The Boring Company. K5 Global focuses on a wide array of industries, including enterprise SaaS, vertical SaaS, fintech, and consumer products. Some notable investments and launched companies include 818 Tequila, Parrot, and The Expert. The firm leverages its extensive network to help innovative companies expand and achieve their growth targets. The management team, led by Michael Kives and Bryan Baum, brings a wealth of experience from various sectors, ensuring robust support for their portfolio companies. K5 Global continues to make significant investments in cutting-edge technologies and groundbreaking startups​.

K50 Ventures, established in 2017 and headquartered in New York, is a venture capital firm dedicated to funding purpose-driven companies at the pre-seed and seed stages. The firm focuses on startups that aim to improve access and affordability in health, finance, and work for the global working class. Notable investments include Mammoth Biosciences, a pioneer in CRISPR technology; Groww, a mobile investing platform in India; and Midi Health, providing specialized healthcare for women over 40. K50 Ventures supports companies that democratize access to financial services, improve healthcare delivery, and empower small businesses and independent workers. Led by founders Ryan Bloomer and Adriel Bercow, K50 Ventures is committed to being the first institutional check and a long-term partner to mission-driven entrepreneurs. They seek founders with a clear vision for creating significant social impact and a solid strategy for execution.

Kairos Ventures, established in 2015 and headquartered in Beverly Hills, California, is a venture capital firm focused on investing in early-stage companies across life sciences, physical sciences, and technology sectors. The firm partners with leading scientists and universities to commercialize groundbreaking discoveries. Their portfolio includes notable companies like MemVerge, which aims to merge computer memory and storage using non-volatile RAM, and Neuro-Bio, a biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Another significant investment is MixComm, a developer of advanced 5G mmWave chips that enhance the efficiency and range of 5G base stations, which was acquired by Sivers Semiconductors in 2022. Kairos Ventures has made over 81 investments and achieved several exits, including Actinobac Biomed and MixComm. The firm is led by founder and CEO James Demetriades, along with a team of experienced professionals who provide strategic support to their portfolio companies.

Kaiser Permanente Ventures (KP Ventures) is a leading venture capital firm dedicated to investing in innovative healthcare solutions. Founded in 1998, KP Ventures has over $500 million in assets under management and focuses on areas such as health information technology, digital health, medical devices, diagnostics, and precision medicine. KP Ventures recently closed its fifth fund at $141 million, which includes contributions from Kaiser Permanente as well as other strategic investors like Tufts Health Plan, Henry Ford Health System, and Highmark Ventures. The firm's investment strategy aims to support companies that address significant unmet needs in the healthcare system, particularly those that align with Kaiser Permanente's mission of providing high-quality, affordable, and accessible care​. Some notable companies in their portfolio include iRhythm, Health Catalyst, and Omada Health. KP Ventures leverages its deep connections with Kaiser Permanente and other healthcare leaders to help its portfolio companies navigate and thrive in the complex healthcare landscape. The team at KP Ventures comprises experienced professionals like Cindy Vanderlinde-Kopper, Amy Belt Raimundo, and co-founders Chris Grant and Chris Stenzel, who bring extensive expertise in healthcare and venture investing.

Kapor Capital, based in Oakland, California, is renowned for its commitment to investing in early-stage tech startups that drive social impact and economic equity. Their portfolio includes notable startups like Bitly, Life360, and AngelList, reflecting their diverse investment range across sectors such as education, health, finance, and justice. Kapor Capital specifically targets tech-driven ventures that aim to close gaps in access for low-income communities and communities of color. Geographically, Kapor Capital focuses primarily on the United States, with a significant presence in the Bay Area. Their investment strategy emphasizes backing founders who leverage their lived experiences to address real community needs. The firm has a robust investment strategy, often leading funding rounds with average check sizes typically between $500,000 and $1 million. They are known for their active involvement in their portfolio companies, providing extensive support beyond capital, including strategic guidance and fostering a dynamic ecosystem for innovation. The fund prides itself on a rigorous commitment to diversity, with a significant portion of their investments going to companies with underrepresented and women founders. In 2023 alone, they deployed $10.7 million across 19 companies, demonstrating their active investment approach. Founders can approach Kapor Capital through their Platform team, which curates events and builds networks to support portfolio companies. Key team members include Mitch Kapor and Freada Kapor Klein, who bring decades of experience in tech and social impact investing. Their leadership has been pivotal in shaping the firm’s mission-driven approach. With a deep commitment to creating a fairer society, Kapor Capital continues to lead the way in impact investing.

Karista is an early-stage venture capital firm based in Paris, specializing in Health, Digital, Technology, and NewSpace sectors. Founded in 2001, the firm has backed over 100 companies, providing more than just financial support. Karista is known for its hands-on approach, helping startups with team structuring, business development, and strategic guidance. Notable investments include Exotrail, a company developing agile space mobility solutions, and Incepto, which raised €27M for its digital health platform. Karista typically invests between €500k and €2.5M in seed and Series A rounds, with follow-on investments up to €6M. They often take board seats to offer deep involvement in the companies they support. Karista's strategy emphasizes early investment in innovative projects with strong value propositions. They co-create with founders, ensuring alignment in vision and goals. The firm manages several funds, including the Paris Region Venture Fund and the SpaceTech fund, focusing on companies ready to impact their markets and improve user lives.

Karman Ventures, formerly known as Moving Capital, is a venture capital firm co-founded by early Uber employees. Based in the United States, Karman primarily focuses on investing in innovative, tech-driven startups across various sectors, including transportation, aerospace, fintech, and consumer services. The firm has built a robust portfolio featuring companies like Whisper Aero, SkyFi, and JOKR, which have shown significant promise in their respective industries. They also have a record of supporting unicorns such as Unit, an open banking solution, and Omio, a platform for booking transportation services globally. Karman Ventures’ investment strategy emphasizes supporting early to growth-stage companies, with an average round size of $31 million. The firm tends to follow rather than lead investment rounds, collaborating with other prominent investors. Despite this, Karman’s network and strategic guidance are pivotal for scaling its portfolio companies, enabling them to grow rapidly within their markets. Karman’s global reach is evident through its diverse portfolio, which includes investments across the US, Europe, and parts of Asia. Karman continues to back companies that demonstrate potential for market disruption and scalability, providing them not only with capital but also strategic expertise drawn from the experience of its founding team and partners. This approach positions Karman Ventures as a dynamic player in the venture capital landscape, blending its roots in tech with a forward-looking investment ethos.

KAUST Innovation Ventures, the venture capital arm of King Abdullah University of Science and Technology (KAUST), focuses on funding early-stage deep tech startups that address significant scientific and technological challenges. The fund invests in sectors such as energy, environment, food, water, advanced materials, robotics, ICT, and health, aligning closely with KAUST's main research areas. The fund supports startups from seed stages, with investments typically ranging from less than $200,000 to up to $2 million. KAUST Innovation Ventures not only provides financial backing but also strategic support, helping startups transition from research to commercialization through its comprehensive innovation ecosystem, which includes the KAUST Entrepreneurship Center and Technology Transfer Office. Notable startups backed by KAUST include Red Sea Farms, which uses saltwater-tolerant crops to address food security and water scarcity in arid regions, and Sadeem, a company developing multi-patented sensor solutions for flood, traffic, weather, and air quality monitoring​. These investments highlight KAUST's commitment to fostering innovation that has a significant impact on both the local Saudi economy and global markets.

Korea Biomedical Industry Development Institute (KBIC) is a pivotal entity in South Korea's life sciences and biomedical sectors. Established to stimulate innovation and economic growth, KBIC supports a wide range of activities in medical, pharmaceutical, and biological fields, focusing on advanced technologies like AI and regenerative medicine. KBIC operates through various initiatives and partnerships to foster a robust ecosystem for biomedical research and development. Key areas of focus include promoting bio-health exports, enhancing R&D capabilities, and nurturing talent within the bio-health industry. The South Korean government provides substantial funding and regulatory support to boost the global competitiveness of Korean bio-pharma companies. The institute emphasizes international collaboration, participating in global conventions and establishing partnerships with leading research institutions and biopharmaceutical companies worldwide. This approach enhances innovation and facilitates the entry of Korean companies into the global market.

Koch Disruptive Technologies is a venture capital firm within Koch Industries, focused on investing in transformative companies across various stages and industries. KDT partners with innovative companies that leverage advanced technologies to create significant economic and societal impacts. The firm’s investment strategy is sector-agnostic, including notable areas like biotechnology, health tech, agriculture, and AI. Some prominent companies in their portfolio include PathAI, which improves pathology diagnostics using AI, and Solugen, which creates environmentally-friendly chemicals through enzymatic reactions. Other investments include Terray Therapeutics, focusing on novel treatments for human diseases, and Andes, which develops bio-based agricultural solutions to enhance crop production. KDT provides more than just financial backing. They offer strategic guidance and leverage Koch Industries’ extensive network to help portfolio companies scale and succeed. The team at KDT includes professionals with diverse expertise, providing valuable support in navigating market challenges and accelerating growth.

Kenetic Capital is a Hong Kong-based venture capital firm that focuses on early-stage investments in blockchain and cryptocurrency technologies. Established in 2016, the firm is dedicated to backing projects that build blockchain infrastructure, data solutions, enterprise tools, trading platforms, and financial services. Kenetic’s goal is to support the next generation of technologies that will drive mass adoption of blockchain, targeting institutional and enterprise use cases. With a global portfolio, Kenetic has made over 130 investments across key regions, including the United States, United Kingdom, China, and Singapore. Notable investments include Alchemy, Blockdaemon, and Boba Network, which are key players in blockchain infrastructure and decentralized applications. Kenetic is highly active in the blockchain space, with investments in emerging Web3 projects like Immutable X, Worldcoin, and Flare, all of which have delivered significant returns​. Kenetic also partners with leading blockchain funds and co-investors, such as NGC Ventures and Fenbushi Capital, strengthening its position as a major player in the blockchain ecosystem.

Keystone Capital is an entrepreneurial holding company and private equity firm founded in 1994 by Kent Dauten and Scott Gwilliam. Based in Chicago, Illinois, Keystone has historically utilized the personal capital of its partners to acquire high-quality, market-leading businesses. In 2021, the firm closed its debut institutional fund, Keystone Capital Fund II, LP, with $420 million in capital commitments, marking a significant evolution in its strategy by including external investors. Keystone Capital focuses on long-term value creation by acquiring and growing businesses across various sectors, including engineering and technical services, tech-enabled services, commercial services and engineered products, and food and beverage manufacturing. The firm emphasizes operational and growth-oriented support for business owners and management teams, aiming for sustainable success. Keystone’s investment philosophy is built on three core values: expertise, conservative investing, and creativity. They conduct thorough preliminary tests to ensure profitability and optimal risk diversification in each transaction, maintain a controlled risk approach to provide investor confidence, and employ creative thinking to overcome barriers and execute complex deals. The firm's recent investments include partnerships with Inspire11 and ClearWater Solutions. Keystone has completed over 110 acquisitions throughout its history and continues to actively manage and grow its portfolio, recently completing ten add-on acquisitions and selling two platform investments in late 2020.

Khosla Ventures, founded by Vinod Khosla in 2004, is a prominent venture capital firm based in Menlo Park, California. The firm is renowned for its investments in early-stage companies across various sectors including internet, computing, mobile, financial services, agriculture, healthcare, and clean technology. Notable investments by Khosla Ventures include high-profile companies like DoorDash, Square, Impossible Foods, Stripe, OpenAI, Instacart, and Nutanix. These companies have not only achieved significant market success but also driven innovation in their respective fields​. Khosla Ventures is known for its willingness to take bold, contrarian bets on groundbreaking ideas. This approach has led to investments in companies that challenge established business models and drive significant industry changes. The firm operates two main funds: a seed fund focused on experimental science and innovation, and a main fund for more traditional ventures from early to later stages. The firm's founder, Vinod Khosla, emphasizes a hands-on approach in supporting entrepreneurs, offering not just capital but also strategic guidance and operational support. This philosophy has made Khosla Ventures a preferred partner for visionary founders looking to make a substantial impact​.

Khwarizmi Ventures, founded in 2018, is a Riyadh-based venture capital firm that invests in early-stage startups across the MENA region. With a strong commitment to supporting innovative founders, the firm manages a $70 million fund and has built a portfolio of over 50 companies across sectors such as fintech, e-commerce, digital health, and proptech. Some of the standout companies in their portfolio include Tamara, a fintech startup, and Eyewa, a leading e-commerce platform for eyewear. Khwarizmi Ventures also boasts notable exits like POSRocket and Fatura, which have further cemented its role as a key player in the region's startup ecosystem. The firm prides itself on an entrepreneur-centric approach, going beyond capital by offering strategic support and leveraging its vast network of regional and global partners to help startups scale. They focus on fast-tracking deals, often leading funding rounds and closing within three to four months, enabling founders to focus on their core business operations. With investments across eight countries, Khwarizmi Ventures plays an instrumental role in empowering startups to achieve regional and global success​. Khwarizmi Ventures’ mission is to partner with exceptional entrepreneurs who are solving complex problems in the ever-evolving markets of the Middle East, North Africa, and Pakistan (MENAP), making it one of the most dynamic VC firms driving innovation in the region.

Kickstart Fund, established in 2008 and headquartered in Cottonwood Heights, Utah, focuses on early-stage investments in the Mountain West region, including Utah and Colorado. The firm has a diverse portfolio with notable investments in companies like Spiff, Artemis Health, and Grow. They primarily invest in sectors such as SaaS, consumer, marketplace, and healthcare, with an emphasis on technology-driven startups. The fund's investment strategy includes leading and participating in pre-seed, seed, and Series A rounds, typically writing initial checks between $250,000 and $1 million. They prioritize companies with strong growth potential and innovative solutions in large markets. Kickstart is known for providing not just capital but also a connected community and expert guidance to help startups scale. Key team members include founder Gavin Christensen, General Partners Dalton Wright and Kat Kennedy, and CFO Alex Soffe, all based in Utah. The team brings a wealth of experience and a hands-on approach to supporting their portfolio companies through operational strategy, networking, and mentorship. Kickstart has demonstrated a strong track record with successful exits, including Cotopaxi and Degreed, highlighting their capability to identify and nurture high-potential startups. Entrepreneurs looking to partner with Kickstart should focus on showcasing their innovative solutions and market potential, aligning with the fund's commitment to driving growth in the Mountain West region​.

Kiko Ventures is a pioneering evergreen climate tech venture investor based in the UK. Launched with €427 million, Kiko focuses on supporting transformative companies developing innovative solutions to the climate crisis. The firm's evergreen structure, backed by IP Group, allows for flexible, long-term investments across various stages, from seed to Series A/B, without the constraints of traditional VC timelines. Kiko Ventures is particularly focused on technologies that can drive the transition to a sustainable and regenerative future. Their portfolio includes companies like C-Capture (carbon capture), Hysata (green hydrogen), and Bramble Energy (hydrogen fuel cells). With a commitment to creating measurable environmental impact alongside financial returns, Kiko invests in areas like renewable energy, carbon-free fuels, and smart energy solutions. Led by industry veterans such as Robert Trezona and Jamie Vollbracht, Kiko Ventures emphasizes flexibility, conviction, and a long-term view, aiming to unlock significant environmental progress while offering entrepreneurs a supportive and strategic investment partner​.

Kima Ventures, established in 2010 by Xavier Niel, is one of the world's most active early-stage investment funds, based in Paris, France. The firm is renowned for its prolific investment pace, funding 2-3 startups per week globally, totaling over 800 investments to date. Kima Ventures provides $150,000 in seed funding to early-stage startups across various sectors, including software, fintech, healthcare, and consumer products. Their portfolio includes notable companies like Wise, Front, and Oyster, and they have achieved 17 unicorns and 111 exits. Kima Ventures supports founders with funding, a robust network, and strategic guidance to accelerate their growth. Key team members include Xavier Niel and Jean De la Rochebrochard, who bring extensive experience and expertise in the tech and startup ecosystems. Kima Ventures' approach is characterized by its rapid decision-making process and a strong commitment to backing innovative and disruptive startups globally. For entrepreneurs, Kima Ventures is an attractive partner due to their extensive experience, active investment approach, and strong support network, which significantly boosts the chances of success for early-stage companies.

Kindred Capital is a London-based venture capital firm that uniquely operates under an "equitable venture" model, where every founder they back becomes a co-owner of the fund. Founded in 2015, Kindred Capital focuses on mission-driven pre-seed and seed-stage investments across Europe and Israel. Their first fund has seen significant success, with 54% of portfolio companies raising Series A funding within three years, a stark contrast to the typical 19% industry average. Notable investments from Kindred Capital include companies like Five, which develops autonomous vehicle software, Paddle, a software sales platform, and Pollen, a marketplace for experiences and travel. They have also recently invested in startups such as BotsAndUs, which focuses on robotics, and Gravity Sketch, a 3D design platform. Kindred's equitable venture model is designed to foster a strong sense of community among founders, encouraging them to support each other. This approach has been well-received, with significant oversubscription in their funds and plans to continue this model with future investments. Their commitment to transparency, speed, and building robust networks around founders is central to their investment strategy.

Kindred Ventures, a seed-stage venture capital firm based in San Francisco, is renowned for its early investments in disruptive startups. Notable investments include Coinbase, Postmates, and Bitski, showcasing their keen eye for high-growth potential. They primarily focus on sectors such as consumer products, healthcare, blockchain, AI, and fintech, emphasizing innovation and transformative technology. Geographically, Kindred Ventures has a strong focus on the United States, particularly the San Francisco Bay Area, but also maintains a global outlook. Their investment strategy is to lead or co-lead rounds, with an average check size of around $3M. They are known for their active involvement in the startups they back, providing not just capital but also strategic guidance and operational support. The team, led by founders Steve Jang and Kanyi Maqubela, brings a wealth of experience from both entrepreneurial and investment backgrounds. They are approachable to mission-driven founders who align with their vision of building impactful and scalable businesses. Startups looking to connect with Kindred Ventures are advised to have a clear, compelling narrative and demonstrate strong potential for market disruption and growth. Overall, Kindred Ventures stands out for its hands-on approach and commitment to fostering innovation across various high-tech industries, leveraging their expertise to support early-stage companies in navigating the complexities of growth and scaling.

King's Health Partners Ventures, now rebranded as Meridian Health Ventures, is the United Kingdom's first NHS-backed venture capital fund, founded in 2021 in London. Born from the King's Health Partners academic health science centre — a collaboration between King's College London, Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS Foundation Trust, and South London and Maudsley NHS Foundation Trust (combined turnover £3.7 billion, 4.8 million patients per year, 40,000 staff) — the fund invests in early-stage digital health, medtech, and enterprise healthcare. The firm leads rounds in its portfolio, with checks typically in the $500K to $3 million range. The success of the initial NHS venture experiment led to significant expansion. In 2025, Meridian Health Ventures launched a €44.7 million transatlantic fund — the world's first transatlantic healthtech fund — backed by UK NHS trusts (Guy's and St Thomas', King's College Hospital, and UCL Hospitals) alongside US healthcare giant Cedars-Sinai Medical Center. In October 2024, the firm also launched Europe's first dedicated mental health technology fund, Innovations in Mental Health (IMH Fund), with the Wellcome Trust as anchor investor and South London and Maudsley NHS as partner. The team of 5 manages 13 portfolio companies whose solutions are now deployed across more than 100 NHS Trusts. Portfolio companies include Doccla (virtual ward platform), deepc (AI radiology), Patchwork (NHS workforce management), Tympa Health (ear care), Apian (drone delivery for NHS), PocDoc (point-of-care testing), MediShout, and JAAQ (most recent investment, Series A, March 2026). Two exits have been recorded, including Phare Health in October 2025. Meridian's institutional relationships across NHS trusts, academic medical centers, and US hospital systems give portfolio companies a structural advantage: direct access to clinical validation environments, real patient populations, and procurement relationships that are typically inaccessible to early-stage healthtech startups.

Kinnevik is a leading investment company founded in 1936, known for its focus on digital consumer businesses. The firm primarily invests in healthcare, software, marketplaces, and climate tech, partnering with innovative entrepreneurs to drive change and improve the way we work, live, and play. Kinnevik’s portfolio includes over 30 companies, such as Cityblock, Mews, Pleo, and Recursion. Kinnevik operates with a long-term investment horizon, providing substantial support to its portfolio companies from early-stage to growth-phase. The firm emphasizes sustainability and believes in investing in business models that generate significant returns while promoting environmental and social responsibility. The executive team is led by CEO Georgi Ganev, with Samuel Sjöström recently appointed as Chief Strategy Officer. The team includes professionals with deep expertise across various sectors, dedicated to fostering the growth of pioneering companies. Kinnevik's investment approach combines financial backing with active involvement in the strategic direction of its portfolio companies, leveraging nearly a century of investment expertise to build successful, sustainable businesses.

K5 Global is a venture capital firm and incubation studio founded in 2018 by Michael Kives and Bryan Baum. Based in San Francisco, the firm supports founders throughout the entire business lifecycle, from seed stages to IPOs. K5 Global has deployed over $1.1 billion in capital and has made 174 direct investments, resulting in 11 exits. Their portfolio includes high-profile companies such as SpaceX, Uber, Coinbase, Lyft, and The Boring Company. K5 Global focuses on a wide array of industries, including enterprise SaaS, vertical SaaS, fintech, and consumer products. Some notable investments and launched companies include 818 Tequila, Parrot, and The Expert. The firm leverages its extensive network to help innovative companies expand and achieve their growth targets. The management team, led by Michael Kives and Bryan Baum, brings a wealth of experience from various sectors, ensuring robust support for their portfolio companies. K5 Global continues to make significant investments in cutting-edge technologies and groundbreaking startups.

Kizoo Technology Capital is a venture capital firm based in Karlsruhe, Germany, founded in 1999 by Michael Greve, Frank Schueler, and Matthias Hornberger. Part of the Mira Holding group alongside sister organization Forever Healthy Foundation, the firm manages a fund of approximately $349 million and has made 54 investments over its history. Kizoo now focuses exclusively on rejuvenation and longevity biotech, backing never-done-before technologies aimed at extending healthy human lifespans by addressing the root causes of aging. Patrick Burgermeister serves as Partner. The firm leads rounds and typically invests at the Seed and Series A stages, with check sizes ranging from $1 million to $10 million. Current active portfolio companies tackle age-related cellular damage from multiple angles: Cellvie (a Harvard spin-off developing mitochondria transfer therapy), Reservoir Neuroscience (brain vascular rejuvenation, $4 million financing in 2024), Cyclarity (arterial plaque removal), Elastrin (tissue decalcification), Revel Pharmaceuticals (collagen crosslink breakers, Yale-originated), and MoglingBio (stem cell rejuvenation). Many of these companies were seeded directly from university research at SENS lab, Yale, Harvard, Clemson, and UC Berkeley. Kizoo's legacy internet and SaaS portfolio includes early seed investments in several German unicorns — Staffbase, Mambu, and Babbel — though the firm no longer makes new investments in those sectors. Kizoo's approach is thesis-driven and deeply hands-on: the team partners with academic founders to help create companies from scratch, often before commercial infrastructure exists. The firm invests across Europe and the United States, reflecting the global nature of longevity science. Three portfolio companies have been acquired, most recently Shyftplan, which was acquired by Maguar in June 2024.

Kjøller is a Danish-founded investment company led by Magnus Kjøller, with its headquarters in Dubai. The firm focuses on two primary areas: venture investments and real estate. Kjøller is deeply involved in both startups and more mature companies, helping them scale and reach their full potential. The company prides itself on providing more than just capital, offering strategic advice, legal support, and networking opportunities to its portfolio companies. Since its inception, Kjøller has invested in over 75 startups worldwide, with 39 active venture investments currently in its portfolio. These investments span various industries, including fintech, e-commerce, media, and greentech, and are primarily focused in Europe and Asia. Some of its notable investments include Digura, Vikings Tech Group, and Kompasbank. Kjøller operates on a lean structure, allowing quick decision-making without the need for external approvals. The company’s approach is rooted in providing direct investments without fees, ensuring a straightforward process for both investors and entrepreneurs. Investors can join the Kjøller Investor List to participate in the firm's deal flow. Overall, Kjøller continues to be a prominent player in the venture capital space, known for its hands-on approach and a broad network that helps startups scale rapidly.

KKR, a global investment giant established in 1976, boasts a diverse and robust portfolio. Among their notable tech investments are GoDaddy, FanDuel, and BMC Software, while in energy and healthcare, they back EP Energy, Ridge Natural Resources, BridgeBio Pharma, and Coastal Carolina Hospital. Their industry focus is broad, spanning private equity, infrastructure, real estate, and credit, with a strong emphasis on sustainability and long-term value creation. Geographically, KKR's investments stretch across the Americas, Europe, and Asia Pacific, reflecting their global reach. Their strategy emphasizes patient, disciplined investing, leveraging deep industry knowledge and a network of expert resources to drive growth in their portfolio companies. They are known for leading investment rounds and typically target companies with substantial growth potential and innovative capabilities. KKR often writes large checks, frequently exceeding $100 million, and takes an active role in guiding their investments, offering strategic advice and operational support. Companies looking to attract KKR's interest should highlight their growth potential, solid business models, and alignment with KKR’s strategic objectives. The firm’s leadership includes Henry Kravis and George Roberts, who bring decades of investment expertise and are based in New York. KKR’s team of over 750 investment professionals worldwide ensures that each investment benefits from specialized expertise and strategic insights. For startups and businesses, aligning proposals with KKR’s focus on sustainable growth and value creation is key to engaging successfully with this investment powerhouse.

Kleiner Perkins, based in Menlo Park, California, is one of Silicon Valley’s most storied venture capital firms, known for its early investments in groundbreaking technology companies. Founded in 1972, the firm has backed over 900 ventures, including iconic names like Amazon, Google, and Genentech​. Kleiner Perkins invests primarily in early-stage companies across a broad range of industries including technology, healthcare, and sustainability. Their investment strategy is characterized by partnering closely with founders from the inception of their companies through to IPO and beyond. This approach has led to successful exits such as Netscape, Cerent, and more recently, Google and Amazon​. The firm has seen significant leadership changes in recent years, with the addition of partners like Mamoon Hamid and Ilya Fushman, who have driven a renewed focus on early-stage investments. Recent funds include the $700 million KP19 and the $750 million KP Select fund, which aim to support high-growth companies in sectors like enterprise software, consumer tech, and fintech​. Kleiner Perkins continues to leverage its deep network and extensive experience to support its portfolio companies in areas such as talent acquisition, go-to-market strategies, and marketing. This hands-on approach, combined with their strategic investments, ensures they remain a key player in fostering innovation and driving growth in the tech ecosystem.